Protocol for Identifying Patients at Risk of AKI
Researchers at Aintree University Hospital (Liverpool, UK) noted that AKI has a mortality rate of 30 percent, which is higher than that for myocardial infarction (8 percent) and stroke (9 percent). They estimated that 15 percent of all inpatients at Aintree University Hospital suffer an AKI, “making it a condition of considerable importance in everyday practice.”
To reduce the toll of AKI at the hospital, and raise awareness of the importance of its prevention, co-authors Thangavelu Chandrasekar, MRCP, and Hsu Pheen Chong, MbChB, developed the STOP-AKI protocol. The programme uses automated electronic alerts to identify patients at risk for developing AKI. STOP-AKI was initially launched in the nephrology ward and then scaled up to become part of routine management for all patients admitted to the hospital.
The researchers used a multidisciplinary streamlined approach, incorporating AKI risk assessment and screening for prevention, early detection using automated e-alerts, and effective intervention (using an evidence-based AKI treatment bundle) to improve patient outcomes by reducing the AKI-associated mortality by 23 percent. At the same time, hospital length of stay fell by 13 percent, or a 2.7-day reduction in length of stay.
See Also: Global Study: 65% of AKI Cases Are Community Acquired
“Improving staff and patient awareness through education, effective monitoring, and handover to primary care on discharge has ensured continuity of care that will hopefully reduce readmissions with AKI,” explained Dr. Chandrasekar. He noted that this required multiple changes to the system at different levels to achieve the reductions in mortality and hospital length of stay.
The research team is currently developing metrics to assess AKI progression and its predictors. They have also rolled out STOP-AKI alerts and management guidelines to the community, enabling much earlier intervention, Dr. Chandrasekar added.
The STOP-AKI protocol is one of several Avoidable Mortality Reduction projects underway at Aintree University Hospital, the others focusing on reducing sepsis and pneumonia.
Source: American Society of Nephrology
Image credit: London Acute Kidney Injury Network
Published on : Sun, 8 Nov 2015
Print as PDF
17 critical parameters from a blood sample as small as 45 µL Not available in the US When the sample is small but your diagnostic needs are big, the ABL90 FLEX PLUS blood gas analyzer provides critical insights with a turnaround time of less than...
The HAMILTON-C6 represents a new Generation of high-end ventilators. The combination of modularity, ease of use, mobility, and advanced features allows you to individualize your patient's ventilation therapy: - State-of-the-art ventilation modes for adult,...
The technical and clinical reference standard for all B·R·A·H·M·S PCT assays. All clinical cut-offs and algorithms were developed based on B·R·A·H·M·S PCT sensitive KRYPTOR. Homogeneous immunoassay for the quantitative d
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...
The HAMILTON-C3 ventilator is a modular high-end ventilation solution for all patient groups. Offering a number of unique features, the HAMILTON-C3 is one of the first ventilators featuring the “Ventilation Autopilot” INTELLiVENT-ASV®. The HAMILTON-C3’s...